Intravenous Glucose
Intravenous Glucose - Related Videos
06:59
Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test
0 Views •
Cited by 7 •
2016
The goal of this protocol is to present a standard method to perform intravenous glucose tolerance tests (IVGTTs) to assess glycemic control in nonhuman primates and assess their metabolic status from healthy to dysmetabolic.
07:22
Discontinuing Intravenous Fluids and a Peripheral Intravenous Line
0 Views •
2023
Source: Madeline Lassche, MSNEd, RN and Katie Baraki, MSN, RN, College of Nursing, University of Utah, UT Intravenous (IV) fluid administration and peripheral IV catheters (PIVs) may be discontinued for a number of reasons. The most common reason for discontinuing IV fluids is that the patient has returned to normal body fluid volume (euvolemia) and is able to maintain adequate oral fluid intake or is being discharged from the hospital. In addition, the Centers for Disease Control Guidelines...
05:52
In Vitro Glucose Depletion Assay: A Fluorescence-Based Method to Quantify Cellular Glucose Uptake via Extracellular Glucose Depletion Measurement
0 Views •
2025
This video demonstrates an in vitro assay to indirectly measure intracellular glucose uptake. The assay uses a fluorescently-labeled glucose analog to establish a correlation between extracellular glucose depletion and intracellular glucose uptake.
02:23
Oral Glucose Tolerance Test (OGTT): Measuring Glucose Metabolism in Mice
0 Views •
2023
This video introduces how to perform an oral glucose tolerance test on a laboratory mouse.
11:39
Peripheral Intravenous Catheter Insertion
0 Views •
2023
Source: Madeline Lassche, MSNEd, RN and Katie Baraki, MSN, RN, College of Nursing, University of Utah, UT The purpose of peripheral intravenous catheter (PIV) insertion is to infuse medications, perform intravenous (IV) fluid therapy, or inject radioactive tracers for special examination procedures. Placing a PIV is an invasive procedure and requires the use of an aseptic, no-touch technique. Common IV venipuncture sites are the arms and hands in adults and the feet in children. According to...
FAQs
Once plasma glucose rises, glucose enters cells through glucose transporters and is processed through glycolysis and related metabolic pathways. These reactions generate usable energy, making the infused carbohydrate rapidly available to tissues. This sequence explains why intravenous delivery can produce an immediate metabolic effect compared with relying on gastrointestinal absorption.
The increase in plasma glucose stimulates pancreatic insulin release. Insulin helps coordinate the cellular response to the newly available glucose, influencing its movement into cells and subsequent use. In pharmacology, this response is important because the metabolic effect reflects both the delivered carbohydrate and the body’s endocrine regulation of circulating glucose.
Concentration and administration rate determine how quickly glucose enters the circulation and how much carbohydrate is delivered over time. Excessive delivery can produce hyperglycemia, osmotic disturbances, or fluid-related complications. Careful selection therefore balances the need for rapid glucose availability against the risks associated with an overly concentrated or rapidly administered solution.
Intravenous glucose bypasses the need for oral intake and gastrointestinal absorption, placing glucose directly into the bloodstream. That route is particularly relevant when a patient cannot consume or absorb nutrients. It also produces a rapid change in plasma glucose, so pharmacologic selection of concentration and rate becomes more important than with ordinary dietary carbohydrate.
Clinicians use intravenous glucose to treat hypoglycemia, prevent low blood glucose, and support patients who cannot consume or absorb nutrients. It may also be included as a vehicle or component of some infusion regimens. The appropriate role depends on whether the immediate goal is glucose correction, nutritional support, or incorporation into a broader infusion plan.
The intended outcome is increased plasma glucose with cellular access to carbohydrate for energy production. However, the same delivery route can cause harm if glucose is supplied excessively, including hyperglycemia, osmotic disturbances, or fluid-related complications. Pharmacologic evaluation therefore considers both the desired correction or support and the consequences of the selected dose delivery conditions.